


## BPK-29

<b>Cat. No.:</b>	HY-122054		
<b>CAS No.:</b>	2143467-62-1		
<b>Molecular Formula:</b>	C <sub>26</sub> H <sub>32</sub> ClN <sub>3</sub> O <sub>3</sub>		
<b>Molecular Weight:</b>	470		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



## BIOLOGICAL ACTIVITY

<b>Description</b>	BPK-29 is a specific ligand that disrupts the atypical orphan nuclear receptor NR0B1-protein (such RBM45 and SNW1) interactions by covalently modifying C274. BPK-29 impairs the anchorage-independent growth of KEAP1-mutant cancer cells <sup>[1]</sup> .
<b>In Vitro</b>	BPK-29 substantially engages NR0B1 with good overall proteomic selectivity in KEAP1-mutant Non-Small Cell Lung Cancers <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Bar-Peled L, et al. Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer. Cell. 2017 Oct 19;171(3):696-709.e23.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA